Hope Rugo (@hoperugo) ranks #3 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 87 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SWITCH, NATALEE, lidERA. CMS Open Payments lists $67,342 in 2025 general payments.
At a Glance
- 11 posts naming a trial in 2026
- 8 trials discussed by name
- Breast Cancer: US #3, Global #4 · 87 physicians engaged
- Leading physician voice: #3 of 23 physicians on SWITCH
- Presented at ESMO 2026, SABCS 2025, ESMO Breast 2026 in 2026
- CMS Open Payments lists $67,342 in 2025 general payments.
This Month
What Hope Rugo has posted in the last 30 days. Updated November 10, 2026.
#ESMO2026 very nice discussion by @LoiSher on novel ADC trials and switching. Be sure to watch on line! Beautiful comments about biomarkers. @OncoAlert https://t.co/KFk4A3xhyw
#ESMO2026 Lei Fan presents a small prospective ADC switching trial largely post topo1 ADCs. Low response and PFS in general. Fast PD on 1st line predicted better ORR on next ADC. New payloads urgently needed. @OncoAlert https://t.co/N4Dz5XSEvl
Very exciting to have Bridget published simultaneously in @ESMO_Open available open access on line!! @drsarahsam @laura_huppert @PTarantinoMD @OncoAlert https://t.co/7PAh48KJoa
@myesmo #ESMO26. The start to an exciting meeting - first two oral BC sessions today. The first session with OS data from Natalee, long term benefit from extended letrozole in B42, huge benefits from 3 novel ADCs in HER2 low/HR+ & Talent. @OncoAlert https://t.co/NsYeBeQYPH
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Hope Rugo
Physicians who reposted Hope Rugo’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #3 | #4 | 87 | 227 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Hope Rugo presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Late-breaking abstract (LBA51)KEYNOTE-B49: pembrolizumab + chemotherapy in PD-L1+ HR+/HER2- advanced breast cancer, final analysis
- SABCS 2025 · OralevERA subgroup analysis (giredestrant + everolimus)EVERA trial profile → · Source: @GaiaGriguolo on X ↗
- ESMO Breast 2026 · Proffered paperCapivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer: Final overall survival results from the phase III CAPItello-291 trialSource: @to_be_elizabeth on X ↗
What Colleagues Are Saying About Hope Rugo
2026 posts by fellow physicians that mention @hoperugo, quoted word for word.
Many thanks to the @OncBrothers for allowing me to be a part of yet another terrific program at #ASCO26! Was thrilled to see my @cityofhope colleague @hoperugo after my panel w @TiansterZhang & @apolo_andrea. Bonus: Got to see the incredible @jhaveri_komal just before she graced the stage!
Oral abstract #BreastCancer session at #ESMO26: super @hoperugo presenting results from KeynoteB49 trial…more translational research is needed to improve our understanding on how to optimize #immunotherapy use in luminal-like disease @OncoAlert @myESMO #pembrolizumab https://t.co/KMFql1Fmzp
2. SARC041: PhIII, Abemaciclib (200mg BID) vs. Placebo in adv/metastatic dedifferentiated liposarcoma - mPFS 9.7mos vs. 1.5mos (HR: 0.38) - ORR: 9% - AEs: Diarrhea (for breast ca, we use 150mg BID… @hoperugo) - What lines wld you use this? Placebo as in 1L 🙄🙄 3/6 https://t.co/eYf9DTY3cl
KN-B49 @hoperugo PDL1+ HR+ MBC after ET tx w/chemo +/-Pembro Chemo: cape, doxil, taxanes Pembro improved mPFS 6 to 6.7 mos; no OS gain Complicated for practice w/ modest gain, ADCs in a competing space, and the pt burden of adding Pembro to oral cape. #ESMO26 @OncoAlert https://t.co/durudyjrCs
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer @hoperugo presents results of KEYNOTE-49 Pembro + CT in HR+ PD-L1+ aBC ⬆️ PFS - improvement is statistically significant but small (6 to 6.7 mos) Bigger difference in the subgroup CPS>=10 @OncoAlert https://t.co/xlU9XWoXAH
What is the value of intercepting molecular resistance in HR+/HER2- metastatic breast cancer? 🎙️Here, our podcast episode dissecting the SERENA6 strategy with the one and only @hoperugo Listen for free here: https://t.co/En3I9klrk9 And don’t forget to follow @breastfriendspd! https://t.co/4D2LuamB9Z
Trials Hope Rugo Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SWITCH | 2 | #3 of 23 | Oct 26, 2026 |
| NATALEE | 2 | #19 of 46 | Oct 23, 2026 |
| lidERA | 2 | #7 of 23 | Sep 12, 2026 |
| OPTIMA (UK) | 2 | #9 of 24 | Aug 8, 2026 |
| BRIDGET | 1 | #6 of 17 | Oct 26, 2026 |
| persevERA | 1 | #12 of 12 | Sep 12, 2026 |
| PATINA | 1 | #5 of 21 | Jun 25, 2026 |
| ASCENT-04 | 1 | #4 of 24 | May 31, 2026 |
Hope Rugo on SWITCH
#ESMO2026 very nice discussion by @LoiSher on novel ADC trials and switching. Be sure to watch on line! Beautiful comments about biomarkers. @OncoAlert https://t.co/KFk4A3xhyw
#ESMO2026 Lei Fan presents a small prospective ADC switching trial largely post topo1 ADCs. Low response and PFS in general. Fast PD on 1st line predicted better ORR on next ADC. New payloads urgently needed. @OncoAlert https://t.co/N4Dz5XSEvl
Hope Rugo on NATALEE
@myesmo #ESMO26. The start to an exciting meeting - first two oral BC sessions today. The first session with OS data from Natalee, long term benefit from extended letrozole in B42, huge benefits from 3 novel ADCs in HER2 low/HR+ & Talent. @OncoAlert https://t.co/NsYeBeQYPH
#asco26 Chia presents interesting analysis of Natalee trial by PAM50. Almost everyone benefits - across intrinsic subsets - and biomarkers may help to identify greater benefit @OncoAlert https://t.co/oaNLrWdokY
Hope Rugo on lidERA
@PTarantinoMD @OncBrothers SERENA-4 trial did not meet primary objective of statistically significant improvement in PFS however a numerical improvement was observed Similar to persevera 1st line Rx isn’t better with an oral SERD. Not surprising given low ESR1m but perplexing given LidERA?
#asco26. Key data from the exciting LidERA study in premenop pts presented by Schmid. Benefit x menopausal status & most Rx with tam in control received LHRHa. Less d/c due to pain. Longer FU needed for medium risk. Q - combo with CDK4/6i or instead? More data T/F @OncoAlert
Hope Rugo on OPTIMA (UK)
OPTIMA mandated OFS for premenopausal women. Agree that at present FU short and in my opinion this data applies to wmn age >40 with N1 disease where we already thot chemo benefit mostly OFS. OFSET will provide key data in the future. https://t.co/0q3UAxYE7j
#asco26. Stein presents data from optima. Using Prosigna to determine chemo benefit in early HR+ BC. Premenopausal women <40 where we stillneed info excluded. Shows Prosigna identifies N+ pts unlikely to benefit from chemo. IMP! 1500 older premen pts included. @OncoAlert https://t.co/MeAaes5bL9
Hope Rugo on BRIDGET
Very exciting to have Bridget published simultaneously in @ESMO_Open available open access on line!! @drsarahsam @laura_huppert @PTarantinoMD @OncoAlert https://t.co/7PAh48KJoa
Hope Rugo on persevERA
@PTarantinoMD @OncBrothers SERENA-4 trial did not meet primary objective of statistically significant improvement in PFS however a numerical improvement was observed Similar to persevera 1st line Rx isn’t better with an oral SERD. Not surprising given low ESR1m but perplexing given LidERA?
Hope Rugo on PATINA
Exciting day with THREE FDA approvals for breast cancer! Patina as maintenance for HR+ HER2 positive MBC, and SG plus pembro or SG alone as 1st line Rx for mTNBC, PDL1+ and neg respectively. Steps forward in improving outcome for patients with MBC, options important! @OncoAlert
Hope Rugo on ASCENT-04
#asco26 back to back presentations by @stolaney1 and Carlos Barrios Ascent 04 and 03. Efficacy of SG maintained across TROP2 expression, tBRCA status and HER2 exp. In ascent04 interesting trend for better PFS in higher TROP2. @OncoAlert https://t.co/uN7N3LKxJb
Hope Rugo’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026 https://t.co/6W2UUCWoWf
#ESMO2026 @RitaNandaMD beautiful and balanced discussion of 2nd set of BC abstracts today. Highlighting her summaries below. https://t.co/6iNHA2UmqS
Another important option for maintenance therapy for HER2+ MBC after induction. More impact in HR neg disease and ET underutilized. Potential to decrease brain mets! Now to evaluate maintenance after TDxd. DB-Guide will evaluate palbo maintenance in HR+/HER2+ MBC. @OncoAlert https://t.co/4gYYD7jeJ6
#ESMO26 nice summary by Antonio Llombart on CNS studies in mHER2 positive disease! Congrats to all. @OncoAlert https://t.co/7TnmuMZQod
#ESMO2026 2 interesting presentations on HER2 isolated brain Mets and LMD. Tucatinib HP for brain Mets and IT HP for LMD. Remarkable efficacy for both! Impact on clinical practice. @OncoAlert https://t.co/RQMmPIPUki
Industry Payments
CMS Open Payments · 2025 general payments
$67,342 across 86 payments